The desires of Yu Jing's Emperor are enforced by his own personal army, and we check out the Infinity Imperial Service action ...

Some great new miniatures are going to be coming to the Sci-Fi world of Infinity soon from Corvus Belli, building up options ...

Never before has Andrew encountered a starter set that was so dead-set against helping the player get started. Read more in this Meeple Mountain review.

As always, there are some stunning Sci-Fi reveals from the team at Corvus Belli, introducing a bunch of new miniatures to existing factions as well as a variety of new characters to shake things up.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising ...

Based on comments from some team owners who described Dallara’s rendering as a warmed-over DW12, Belli’s involvement has had an immediate impact. According to those who’ve seen Belli’s influence on ...

Corvus Pharmaceuticals highlighted significant progress for soquelitinib, including ongoing Phase 3 trials for T-cell lymphoma and advancements in atopic dermatitis studies. The company has ...

The Infinity Nikki 1.4 adds nine brand new outfits, including four that you can claim completely for free. While there's only one Banner running at the start of version 1.4 in Infinity Nikki (with ...

Supplied Dubai: Dubai’s Roads and Transport Authority (RTA) today inaugurated a major bridge to enhance traffic movement from Infinity Bridge through Al Mina Street to the intersection of Sheikh ...

Infold Games announced some of the new elements we can expect in future updates for Infinity Nikki, and these include a new event map, general updates, and a new control customization option.

(RTTNews) - Corvus Pharmaceuticals, Inc.(CRVS), a clinical-stage biopharmaceutical company, Thursday reported positive data from its Phase 1/1b study of soquelitinib for the treatment of patients ...